{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:37:11Z","timestamp":1760747831703,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1141295"],"award-info":[{"award-number":["APP1141295"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejca.2023.04.017","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T01:41:21Z","timestamp":1682991681000},"page":"112901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["External validation in an Australian population of the EORTC-DeCOG nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodes"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9197-5270","authenticated-orcid":false,"given":"Andrew T.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-6800","authenticated-orcid":false,"given":"Jenaleen","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-1253","authenticated-orcid":false,"given":"Sydney","family":"Ch\u2019ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander H.R.","family":"Varey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.04.017_bib1","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jso.25442","article-title":"Current management of regional lymph nodes in patients with melanoma","volume":"119","author":"Bartlett","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2023.04.017_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1245\/s10434-019-07830-w","article-title":"The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes)","volume":"27","author":"Bello","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.04.017_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.04.017_bib4","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.017_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2020.04.022","article-title":"The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection","volume":"134","author":"Verver","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.04.017_bib6","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.04.017_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5","article-title":"What do we mean by validating a prognostic model?","volume":"19","author":"Altman","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2023.04.017_bib8","article-title":"A nomogram combining a four-gene biomarker and clinical factors for predicting survival of melanoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2023.04.017_bib9","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/01.ju.0000127733.01845.57","article-title":"Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure)","volume":"171","author":"Greene","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2023.04.017_bib10","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1245\/s10434-008-0077-x","article-title":"Validation of a nomogram to predict the presence of sentinel lymph node metastases in melanoma","volume":"15","author":"Pinero","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.04.017_bib11","first-page":"550","article-title":"Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data","volume":"108","author":"El Sharouni","year":"2021","journal-title":"Br\u00a0J\u00a0Surg"},{"key":"10.1016\/j.ejca.2023.04.017_bib12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.017_bib13","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1200\/JCO.2005.11.138","article-title":"Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis","volume":"23","author":"Hagerty","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.017_bib14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2023.04.017_bib15","doi-asserted-by":"crossref","first-page":"s163","DOI":"10.25251\/skin.7.supp.163","article-title":"Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB\/C melanoma (CheckMate 76K)","volume":"7","author":"Long","year":"2023","journal-title":"SKIN J Cutan Med"},{"key":"10.1016\/j.ejca.2023.04.017_bib16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejca.2023.03.011","article-title":"Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?","volume":"186","author":"Varey","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.04.017_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2022.11.033","article-title":"Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB\/C melanoma: a population-based analysis","volume":"88","author":"Sharon","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2023.04.017_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.017_bib19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.04.017_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.04.017_bib21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.017_bib22","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.017_bib23","doi-asserted-by":"crossref","first-page":"12462","DOI":"10.1038\/s41598-020-69330-2","article-title":"A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients","volume":"10","author":"Liao","year":"2020","journal-title":"Sci Rep"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:52Z","timestamp":1760733712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923002186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":23,"alternative-id":["S0959804923002186"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External validation in an Australian population of the EORTC-DeCOG nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112901"}}